# Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

> **NCT06670352** · PHASE2 · RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- IgA Nephropathy (IgAN)

## Interventions

- **DRUG:** Placebo
- **DRUG:** HSK39297 50mgBID
- **DRUG:** HSK39297 100mgBID
- **DRUG:** HSK39297 200mgQD

## Key facts

- **NCT ID:** NCT06670352
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-12
- **Primary completion:** 2025-11-23
- **Final completion:** 2026-03-15
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06670352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06670352, "Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06670352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*